Loading...
In several observational studies, hormone therapy (HT) has been associated with elevated risk for ovarian cancer. In this new study, Danish investigators prospectively followed 900,000 women (age range, 50–79) who had at least one ovary and no hormone sensitive cancers; development of ovarian cancer was linked to pharmacy registry data.
During mean follow-up of 8 years, 2681 cases of epithelial ovarian cancer were diagnosed. In analyses adjusted for numerous demographic and reproductive factors, risk for epithelial ovarian cancer was elevated by 44% (highly significant) for current users of any HT, and by 15% (barely significant) for former users. Risk declined after cessation of HT and approached baseline after 2 years. There was no differe…